Trial Profile
Use of TRC Autologous Bone Marrow Cells in Posterolateral Lumbar Spine Fusion
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 14 Mar 2017
Price :
$35
*
At a glance
- Drugs Ixmyelocel-T (Primary)
- Indications Intraoperative complications
- Focus Adverse reactions
- Sponsors Vericel Corporation
- 07 Mar 2017 Status changed to discontinued due to business reasons (not safety reasons).
- 02 Dec 2014 New trial record